Repression of YAP by NCTD disrupts NSCLC progression

@inproceedings{Guo2017RepressionOY,
  title={Repression of YAP by NCTD disrupts NSCLC progression},
  author={Jiwei Guo and Yan Ting Wu and Lijuan Yang and Jing Du and Kaikai Gong and Weiwei Chen and Juanjuan Dai and Xuelin Li and Sichuan Xi},
  booktitle={Oncotarget},
  year={2017}
}
The efficacy of available lung cancer therapeutic interference is significantly limited by various resistance mechanisms to those drugs. Activation of the oncogene YAP underlying the initiation, progression, and metastasis of lung cancer associates with poor prognosis and confers drug resistance against targeted therapy. In this study, we evaluated the specificity of norcantharidin (NCTD) in repressing YAP to inhibit non-small cell lung carcinoma (NSCLC) progression. Our study revealed that YAP… CONTINUE READING